Cipla is currently trading at Rs. 923.50, up by 16.65 points or 1.84% from its previous closing of Rs. 906.85 on the BSE. The scrip opened at Rs. 910.00 and has touched a high and low of Rs. 925.25 and Rs. 908.90 respectively. So far 58696 shares were traded on the counter. The BSE group … Read more
InvaGen Pharmaceuticals Inc., a subsidiary of the leading global pharmaceutical company Cipla, has entered into definitive agreements with two closing stages for a proposed acquisition of Avenue Therapeutics, Inc., a Fortress Biotech company focused on the development and commercialization of intravenous (IV) Tramadol. At the first stage closing, InvaGen or its affiliates will acquire, through … Read more
